Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

BACKGROUND AND OBJECTIVES: Short-term studies focused on once-monthly paliperidone palmitate (PP) at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Patient Prefer Adherence
Glavni autori: González-Rodríguez, Alexandre, Catalán, Rosa, Penadés, Rafael, Garcia-Rizo, Clemente, Bioque, Miquel, Parellada, Eduard, Bernardo, Miquel
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459629/
https://ncbi.nlm.nih.gov/pubmed/26082620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S63948
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items